Development and In vitro Assessment of Topical Microemulsion Based Pluronic-Lecithin Organogel for the Management of Arthritic Pain

Topical delivery of NSAIDs through organogels might transport lornoxicam to the site of action, minimizing gastrointestinal problems and adverse effects. In the current investigation, a lecithin organogel containing lornoxicam was made by microemulsion method. For this purpose, a certain amount of pure soya lecithin was dispersed in suitable isopropyl myristate as a dispersant and emulsifier at room temperature to form the oily phase. The lecithin was completely dissolved in the combination by the next morning. Sorbic acid was then added to the mixture as a preservative, Pluronic F-127 and potassium sorbate were weighed out, and then they were mixed with cold water to create an aqueous phase, and menthol was added. On the next morning, lornoxicam, the active component, became soluble in polyethylene glycol-400 and combined with the lecithin isopropyl palmitate mixture. The oily portion was agitated using a mechanical stirrer at 400 rpm while the aqueous phase was introduced gradually. The lornoxicam organogel preparation was it was assessed for its physical appearance, organoleptic characteristics, consistency, gelation temperature, drug content, and in vitro release studies. The active ingredient content of formulation F5 was the highest at 93.33. Formulations F4 and F5 were selected for kinetic studies because they had all physical characteristics under reasonable limits, the active ingredient level was the greatest, and the active ingredient release was the fastest in eight hours. The transdermal organogel formulation of lornoxicam was found to be effective for topical distribution of the drug and when administered topically, it has strong anti-inflammatory and anti-rheumatic action.